
|Articles|October 1, 2005
Setback for Genentech
The FDA has denied Genentech's request to fast-track the application for its age-related macular degeneration (AMD) agent, Lucentis (ranibizumab). In response, Genentech announced it plans to file a complete Biologics License Application (BLA) for Lucentis for the treatment of neovascular AMD in December 2005, in a bid to speed up the process. Although the FDA rejected Genentech's request for fast-track designation, this should not affect the timing for BLA submission or the potential to obtain priority review.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
3
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











